Exelixis, Ryvu Therapeutics to develop new targeted cancer therapies
These therapies will be developed using Ryvu’s stimulator of interferon genes (STING) technology. The deal expands Exelixis’ biotherapeutics portfolio by combining its tumour-specific targeting approaches with the Ryvu’s